Drug
Aln 6222
Aln 6222: highest development phase Phase 1, developed by Alnylam Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Alnylam Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| ALN-6222 NCT07624071 | Phase 1 | Obesity |
Latest
No recent events.
Follow Aln 6222 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.